Overview
ROIV market data
Price History
ROIV price chart · 1M
- O
- 36.85
- H
- 37.79
- L
- 36.54
- C
- 37.40
- Vol
- 237,509.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $36.85
- Previous Close
- $36.76
- Day High
- $37.79
- Day Low
- $36.54
- 52 Week High
- $37.92
- 52 Week Low
- $27.48
- 7 Day Return
- +1.56%
- 30 Day Return
- +10.59%
- 90 Day Return
- +24.65%
- 1 Year Return
- +35.95%
- Daily Notional Volume
- $8.9M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.43 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.11 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3,535.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $11.60 – $37.97 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $26.2B · P/B 4.38 · P/S 3,479.27.
Company News
Roivant's Priovant Says FDA Approved LISRAYA For Dermatomyositis In Adults, First Targeted Therapy For The Disease; Available In U.S. ImmediatelyBenzinga · Aug 27, 2026, 7:29 PM
Why Is Arbutus Biopharma Stock Gaining Friday?Benzinga · Aug 21, 2026, 4:36 PM
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $46Benzinga · Aug 10, 2026, 3:07 PM
Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $42Benzinga · Aug 7, 2026, 4:57 PM
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $41Benzinga · Aug 7, 2026, 1:12 PM
Roivant's Priovant Announces First Patients Enrolled In Global Phase 3 BEACON+ Study Of Brepocitinib In Cutaneous Sarcoidosis; Topline Data Expected In 2028Benzinga · Aug 6, 2026, 11:21 AM
8-K filing — Roivant Sciences Ltd. (ROIV)SEC EDGAR · Aug 6, 2026, 11:13 AM
Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M EstimateBenzinga · Aug 6, 2026, 11:12 AM
Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis StudyBenzinga · Jun 25, 2026, 6:00 PM